RLAY - Relay Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

190.5M

Cash

871.6M

Avg Qtr Burn

-64.74M

Short % of Float

22.21%

Insider Ownership

2.42%

Institutional Own.

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RLY-4008 (FGFR2 inhibitor) Details Solid tumor/s, Intrahepatic cholangiocarcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RLY-2608 (PI3Kα inhibitor) Details Breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GDC-1971 (RLY-1971) Details Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.